New drugs to watch in 2020

Most drug makers hope to develop a blockbuster or two. Which lucky manufacturers will hit the coveted $1 billion mark with their new drugs?

BioWorld, along with Clarivate Analytics, are out with a new report today highlighting 11 new drugs slated to reach the market this year that might reach blockbuster status by 2024. 

The report highlights Biomarin’s hemophilia A gene therapy, Valrox, as a contender, along with Rybelsus — a “holy grail” oral semaglutide drug for diabetes. Celgene’s CAR-T lymphoma drug Liso-cel, developed by Juno Therapeutics, also makes the cut.